Juno Therapeutics, Inc. (NASDAQ:JUNO) EVP Robert Azelby sold 1,816 shares of the company’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36. Following the completion of the sale, the executive vice president now owns 70,832 shares of the company’s stock, valued at approximately $3,184,606.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Robert Azelby also recently made the following trade(s):
- On Thursday, November 2nd, Robert Azelby sold 6,666 shares of Juno Therapeutics stock. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70.
Shares of Juno Therapeutics, Inc. (JUNO) traded up $0.32 during midday trading on Thursday, hitting $45.03. The stock had a trading volume of 1,422,279 shares, compared to its average volume of 2,107,983. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics, Inc. has a 12 month low of $17.52 and a 12 month high of $63.45.
JUNO has been the subject of a number of recent analyst reports. Wedbush upgraded shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price objective for the company in a research report on Tuesday, August 29th. Wells Fargo & Company reiterated an “outperform” rating and set a $54.00 target price (up previously from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Raymond James Financial increased their target price on Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a report on Friday, November 3rd. Goldman Sachs Group reiterated a “neutral” rating and set a $44.00 target price on shares of Juno Therapeutics in a report on Friday, October 6th. Finally, Standpoint Research reiterated a “reduce” rating on shares of Juno Therapeutics in a report on Thursday, August 31st. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the stock. Juno Therapeutics has a consensus rating of “Hold” and an average price target of $45.48.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Advisor Group Inc. grew its holdings in shares of Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,439 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares in the last quarter. Pacad Investment Ltd. bought a new position in shares of Juno Therapeutics in the 2nd quarter valued at about $105,000. Bronfman E.L. Rothschild L.P. grew its holdings in shares of Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 3,559 shares in the last quarter. Finally, QS Investors LLC bought a new position in shares of Juno Therapeutics in the 2nd quarter valued at about $135,000. Institutional investors own 69.94% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/12/21/juno-therapeutics-inc-juno-evp-robert-azelby-sells-1816-shares-of-stock.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
What are top analysts saying about Juno Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics and related companies.